GlassScriptPhysician profile
Amanda G Hecker
NPI 1205285921
$5,270.98
in general payments reported to CMS, 2019-2025
23 companies · $59.58 in 2025
The $59.58 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $130 · 2021: $818 · 2022: $2,122 · 2023: $1,589 · 2024: $184 · 2025: $59.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $865.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $738.71 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $590.38 | 2022-2023 | Rexulti, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436.89 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $348.38 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $300.18 | 2021-2023 | Austedo |
| Neurocrine Biosciences, INC. | $279.13 | 2020-2023 | Ingrezza |
| Lundbeck LLC | $254.61 | 2021-2023 | Rexulti |
| Almatica Pharma LLC | $252.58 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $250.47 | 2021-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $163.65 | 2022-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $143.14 | 2019-2021 | |
| Corium, LLC | $136.02 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $114.62 | 2021-2022 | |
| Bausch Health US, LLC | $113.61 | 2022-2023 | Aplenzin, Wellbutrin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $70.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.08 | 2021-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $46.61 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $34.57 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $22.39 | 2022 | |
| Livanova USA, INC. | $20.42 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Tris Pharma INC | $16.73 | 2023 | Dyanavel Xr |
| Eisai INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.